Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk
Riccardo Caccialanza(University of Pavia), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Valeria Borioli(Istituti di Ricovero e Cura a Carattere Scientifico), Jessica Saddi(Policlinico San Matteo Fondazione), Marilisa Caraccia(Policlinico San Matteo Fondazione), Angioletta Lasagna(University of Pavia), Vittorina Zagonel(Istituto Oncologico Veneto), Silvia Cappello(Ludwig-Maximilians-Universität München), Ilaria Imarisio(University of Pavia), Catherine Klersy(Policlinico San Matteo Fondazione), Emanuele Cereda(GTx (United States)), Mariateresa Nardi(Istituti di Ricovero e Cura a Carattere Scientifico), Annalisa Turri(Policlinico San Matteo Fondazione)
Cited by 9
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569